Differences Exist in Precision Oncology Drug Eligibility Among Patient Ancestral Groups

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 14, 2025.

By Lori Solomon HealthDay Reporter

TUESDAY, Jan. 14, 2025 -- Ancestry-based differences in frequencies of biomarkers that drive patient selection for treatment with precision oncology drugs currently exist, according to a study published online Jan. 9 in JAMA Oncology.

Kanika Arora, from Memorial Sloan Kettering Cancer Center in New York City, and colleagues examined whether patients with cancer from different ancestral backgrounds benefited equally from U.S. Food and Drug Administration precision oncology drug approvals from January 1998 to December 2023. The analysis included a retrospective analysis of samples from 59,433 patients with solid cancers who underwent clinical sequencing using the integrated mutation profiling of actionable cancer targets (MSK-IMPACT) assay between January 2014 and December 2022.

The researchers found that the approval of the EGFR-tyrosine kinase inhibitor erlotinib for patients with EGFR-mutant lung cancers in 2013 disproportionately benefited patients of East Asian and South Asian ancestries, leading to higher patient fractions with level 1 biomarkers in these ancestral groups versus other populations. Patients of African ancestry had the lowest fraction of level 1 biomarkers compared with other groups from 2019 onward, while the increase in precision oncology drug approvals from 2019 to 2020 had a notable positive impact on clinical actionability for patients of European ancestry.

"These differences may exacerbate the systemic disparities in clinical outcomes in patients of African ancestry due to existing deficiencies in their access to cancer care," the authors write.

Several authors disclosed ties to the pharmaceutical and biotechnology industries.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-01-15 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords